Cuprina (Cayman) (CUPR) vs Nephros (NEPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nephros (NEPH) has outperformed Cuprina (Cayman) (CUPR) over the past year, losing 36.2% versus a loss of 78.8%. Nephros is the larger company by market cap ($35.7 million vs $13.3 million), about 2.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUPR | NEPH |
|---|---|---|
| Share price | $1.90 | $3.29 |
| Market cap | $13.31M | $35.73M |
| 1-day change | -4.52% | +2.81% |
| YTD return | -40.63% | -32.58% |
| 1-year return | -78.79% | -36.24% |
| 5-year return | — | -57.60% |
| P/E ratio (TTM) | — | 21.93 |
| Forward P/E | — | 15.67 |
| EPS (TTM) | $-1.40 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.80 | $6.42 |
| 52-week low | $1.45 | $2.66 |
| Distance from 52-week high | -87.16% | -48.75% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +89.97% |
| Average volume | 94.31K | 27.59K |
| Shares outstanding | 5.24M | 10.86M |
| Employees | 10 | 36 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nephros is about 2.7 times larger than Cuprina (Cayman) by market value ($35.73M vs $13.31M).
- NEPH has outperformed CUPR by 42.6 percentage points over the past year.
About Cuprina (Cayman)
CUPR stock →Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name.
Health Care · Industrial Specialties · 10 employees
About Nephros
NEPH stock →Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Health Care · Medical/Dental Instruments · 36 employees
CUPR vs NEPH FAQ
Which is bigger, Cuprina (Cayman) or Nephros?
Nephros (NEPH) is larger, with a market capitalization of $35.73M compared with $13.31M for Cuprina (Cayman) (CUPR).
Which stock has performed better over the past year, CUPR or NEPH?
NEPH returned -36.24% over the past 12 months, compared with -78.79% for CUPR (price return, excluding dividends). Past performance does not predict future results.
Are Cuprina (Cayman) and Nephros in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Cuprina (Cayman) and Medical/Dental Instruments for Nephros.